Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,netReceivables,inventory,accountsPayable,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,changeInCash,repurchaseOfStock,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,changeToNetincome,capitalExpenditures,issuanceOfStock,effectOfExchangeRate,WC,language,region,quoteType,triggerable,quoteSourceName,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,priceHint,regularMarketChangePercent,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,currency,esgPopulated,tradeable,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchange,shortName,exchangeDataDelayedBy,market,marketState,epsTrailingTwelveMonths,twoHundredDayAverageChangePercent,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,ETBI,-5290917.0,2057549952,-12046,,-1632887,,-1632887,1664217,-69211,-1721382,-1721382,,,,,,0,23138,1744520,92349,88495,,-1632887,-1632887,13218261.0,6961001.0,-5290917.0,96014.0,1670084.0,11320.0,-18399319.0,-121179.0,-1.0,4911.0,6961001.0,-121179.0,701815.0,168270.0,800000.0,28735.0,112944.0,653783.0,551591.0,-51684.0,1380478.0,1308553.0,-522864.0,-73665.0,-71925.0,-1330534.0,73695.0,-21635.0,288431.0,-117359.0,-51684.0,,,-6792731.0,en-US,US,EQUITY,False,Delayed Quote,107186,0.0009900001,99.00001,1.0E-5 - 0.03,-0.029,-0.96666664,1e-05,0.03,-0.003,0.0028151516,-0.0018151515,-0.6447793,0.003557037,-0.002557037,2057550,4,0.0,-0.33333334,15,America/New_York,EDT,-14400000,0.001 - 0.001,0.001,0.0,0.0,0,0,finmb_3599877,Other OTC,Eastgate Biotech Corp.,USD,99270,USD,False,False,0.001,1630336123,0.0,0.001,0.001,0.001,30000,PNK,EASTGATE BIOTECH CORP,0,us_market,REGULAR,-0.007,-0.7188671,2.68,,,0.03,0.0,0.0028,0.0036,99.27k,107.19k,2.06B,,1.49B,0.00%,0.04%,,,,,,,,,,,,,,,,"Dec 30, 2016","Sep 29, 2017",0.00%,"-2,640.79%",,,137.64k,0.00,,,-3.55M,-3.82M,-0.0070,,4.91k,0,3.08M,,0.02,-0.00,-1.76M,,Value,M5J 2L4,,2,"Eastgate Biotech Corp., a development stage company, develops novel formulations of natural compounds and pharmaceutical products. The company is developing pharmaceutical products, such as Lorazepam oral spray for acute seizures emergency treatment; Ketoconazole 2% topical ointment for treatment of skin fungal infections; and Metformin chewable/ sublingual tablets for treatment of type 2 diabetes. It is also developing natural products and dietary supplements, including E-drops Nano and PURALEN that are self-nanoemulsifying compositions containing natural essential oils for oral administration; Glucora, a soft gelatin capsule with Banaba extract in self-emulsifying formulation for oral administration; URBAN POWER, a soft gelatin capsule with Ursolic acid and Banaba extract in self-emulsifying formulation for oral administration; Vitamin D3 nanoemulsion, a nanoemulsion with cholecalciferol; and Cleanezze, a hand sanitizer containing oil. Eastgate Biotech Corp. has collaboration with Biotech Corp. to develop a vaccine against COVID-19. The company was formerly known as Eastgate Acquisitions Corporation and changed its name to Eastgate Biotech Corp. in December 2014. Eastgate Biotech Corp. was founded in 1999 and is based in Toronto, Canada.",Toronto,647-692-0652,ON,1483142400,Canada,http://www.EastGateBiotech.com,86400,65 Harbour Square,,Suite 2203
t-1,ETBI,-4024691.0,2057549952,94440,,-714822,,-714822,435601,57574,-472467,-472467,,-217108.0,,,,0,114500,586967,56926,-242355,,-714822,-714822,12203510.0,5816441.0,-4024691.0,94841.0,1791950.0,11367.0,-16297925.0,58357.0,,78576.0,5816441.0,58357.0,845102.0,946848.0,,868272.0,,462437.0,72933.0,-51684.0,-21457.0,170468.0,644729.0,69228.0,-71925.0,-131034.0,73695.0,-21635.0,-23272.0,-110601.0,-51684.0,191925.0,29794.0,-4869593.0,en-US,US,EQUITY,False,Delayed Quote,107186,0.0009900001,99.00001,1.0E-5 - 0.03,-0.029,-0.96666664,1e-05,0.03,-0.003,0.0028151516,-0.0018151515,-0.6447793,0.003557037,-0.002557037,2057550,4,0.0,-0.33333334,15,America/New_York,EDT,-14400000,0.001 - 0.001,0.001,0.0,0.0,0,0,finmb_3599877,Other OTC,Eastgate Biotech Corp.,USD,99270,USD,False,False,0.001,1630336123,0.0,0.001,0.001,0.001,30000,PNK,EASTGATE BIOTECH CORP,0,us_market,REGULAR,-0.007,-0.7188671,2.68,,,0.03,0.0,0.0028,0.0036,99.27k,107.19k,2.06B,,1.49B,0.00%,0.04%,,,,,,,,,,,,,,,,"Dec 30, 2016","Sep 29, 2017",0.00%,"-2,640.79%",,,137.64k,0.00,,,-3.55M,-3.82M,-0.0070,,4.91k,0,3.08M,,0.02,-0.00,-1.76M,,Value,M5J 2L4,,2,"Eastgate Biotech Corp., a development stage company, develops novel formulations of natural compounds and pharmaceutical products. The company is developing pharmaceutical products, such as Lorazepam oral spray for acute seizures emergency treatment; Ketoconazole 2% topical ointment for treatment of skin fungal infections; and Metformin chewable/ sublingual tablets for treatment of type 2 diabetes. It is also developing natural products and dietary supplements, including E-drops Nano and PURALEN that are self-nanoemulsifying compositions containing natural essential oils for oral administration; Glucora, a soft gelatin capsule with Banaba extract in self-emulsifying formulation for oral administration; URBAN POWER, a soft gelatin capsule with Ursolic acid and Banaba extract in self-emulsifying formulation for oral administration; Vitamin D3 nanoemulsion, a nanoemulsion with cholecalciferol; and Cleanezze, a hand sanitizer containing oil. Eastgate Biotech Corp. has collaboration with Biotech Corp. to develop a vaccine against COVID-19. The company was formerly known as Eastgate Acquisitions Corporation and changed its name to Eastgate Biotech Corp. in December 2014. Eastgate Biotech Corp. was founded in 1999 and is based in Toronto, Canada.",Toronto,647-692-0652,ON,1483142400,Canada,http://www.EastGateBiotech.com,86400,65 Harbour Square,,Suite 2203
t-2,ETBI,-4924786.0,2057549952,175990,,-952111,,-952111,738698,0,-914688,-914688,,-37424.0,,,,0,0,914688,0,-37423,,-952111,-952111,10626491.0,4934134.0,-4924786.0,93958.0,9348.0,3262.0,-15583102.0,28563.0,,9348.0,4894110.0,28563.0,,9348.0,,,,423705.0,112039.0,-51684.0,141966.0,141966.0,62063.0,9348.0,-71925.0,-121479.0,73695.0,-21635.0,-23272.0,656530.0,-51684.0,191925.0,-11139.0,-4884762.0,en-US,US,EQUITY,False,Delayed Quote,107186,0.0009900001,99.00001,1.0E-5 - 0.03,-0.029,-0.96666664,1e-05,0.03,-0.003,0.0028151516,-0.0018151515,-0.6447793,0.003557037,-0.002557037,2057550,4,0.0,-0.33333334,15,America/New_York,EDT,-14400000,0.001 - 0.001,0.001,0.0,0.0,0,0,finmb_3599877,Other OTC,Eastgate Biotech Corp.,USD,99270,USD,False,False,0.001,1630336123,0.0,0.001,0.001,0.001,30000,PNK,EASTGATE BIOTECH CORP,0,us_market,REGULAR,-0.007,-0.7188671,2.68,,,0.03,0.0,0.0028,0.0036,99.27k,107.19k,2.06B,,1.49B,0.00%,0.04%,,,,,,,,,,,,,,,,"Dec 30, 2016","Sep 29, 2017",0.00%,"-2,640.79%",,,137.64k,0.00,,,-3.55M,-3.82M,-0.0070,,4.91k,0,3.08M,,0.02,-0.00,-1.76M,,Value,M5J 2L4,,2,"Eastgate Biotech Corp., a development stage company, develops novel formulations of natural compounds and pharmaceutical products. The company is developing pharmaceutical products, such as Lorazepam oral spray for acute seizures emergency treatment; Ketoconazole 2% topical ointment for treatment of skin fungal infections; and Metformin chewable/ sublingual tablets for treatment of type 2 diabetes. It is also developing natural products and dietary supplements, including E-drops Nano and PURALEN that are self-nanoemulsifying compositions containing natural essential oils for oral administration; Glucora, a soft gelatin capsule with Banaba extract in self-emulsifying formulation for oral administration; URBAN POWER, a soft gelatin capsule with Ursolic acid and Banaba extract in self-emulsifying formulation for oral administration; Vitamin D3 nanoemulsion, a nanoemulsion with cholecalciferol; and Cleanezze, a hand sanitizer containing oil. Eastgate Biotech Corp. has collaboration with Biotech Corp. to develop a vaccine against COVID-19. The company was formerly known as Eastgate Acquisitions Corporation and changed its name to Eastgate Biotech Corp. in December 2014. Eastgate Biotech Corp. was founded in 1999 and is based in Toronto, Canada.",Toronto,647-692-0652,ON,1483142400,Canada,http://www.EastGateBiotech.com,86400,65 Harbour Square,,Suite 2203
t-3,ETBI,-4618066.0,2057549952,120707,,-569237,,-569237,405491,0,-526198,-526198,,-43039.0,,,,0,0,526198,0,-43039,,-569237,-569237,9970127.0,4618066.0,-4618066.0,93143.0,,3096.0,-14630991.0,39702.0,,,4578042.0,39702.0,,,,,,279688.0,26106.0,-51684.0,127395.0,127395.0,297066.0,9348.0,-71925.0,-168852.0,73695.0,-21635.0,-23272.0,77213.0,-51684.0,191925.0,41457.0,,en-US,US,EQUITY,False,Delayed Quote,107186,0.0009900001,99.00001,1.0E-5 - 0.03,-0.029,-0.96666664,1e-05,0.03,-0.003,0.0028151516,-0.0018151515,-0.6447793,0.003557037,-0.002557037,2057550,4,0.0,-0.33333334,15,America/New_York,EDT,-14400000,0.001 - 0.001,0.001,0.0,0.0,0,0,finmb_3599877,Other OTC,Eastgate Biotech Corp.,USD,99270,USD,False,False,0.001,1630336123,0.0,0.001,0.001,0.001,30000,PNK,EASTGATE BIOTECH CORP,0,us_market,REGULAR,-0.007,-0.7188671,2.68,,,0.03,0.0,0.0028,0.0036,99.27k,107.19k,2.06B,,1.49B,0.00%,0.04%,,,,,,,,,,,,,,,,"Dec 30, 2016","Sep 29, 2017",0.00%,"-2,640.79%",,,137.64k,0.00,,,-3.55M,-3.82M,-0.0070,,4.91k,0,3.08M,,0.02,-0.00,-1.76M,,Value,M5J 2L4,,2,"Eastgate Biotech Corp., a development stage company, develops novel formulations of natural compounds and pharmaceutical products. The company is developing pharmaceutical products, such as Lorazepam oral spray for acute seizures emergency treatment; Ketoconazole 2% topical ointment for treatment of skin fungal infections; and Metformin chewable/ sublingual tablets for treatment of type 2 diabetes. It is also developing natural products and dietary supplements, including E-drops Nano and PURALEN that are self-nanoemulsifying compositions containing natural essential oils for oral administration; Glucora, a soft gelatin capsule with Banaba extract in self-emulsifying formulation for oral administration; URBAN POWER, a soft gelatin capsule with Ursolic acid and Banaba extract in self-emulsifying formulation for oral administration; Vitamin D3 nanoemulsion, a nanoemulsion with cholecalciferol; and Cleanezze, a hand sanitizer containing oil. Eastgate Biotech Corp. has collaboration with Biotech Corp. to develop a vaccine against COVID-19. The company was formerly known as Eastgate Acquisitions Corporation and changed its name to Eastgate Biotech Corp. in December 2014. Eastgate Biotech Corp. was founded in 1999 and is based in Toronto, Canada.",Toronto,647-692-0652,ON,1483142400,Canada,http://www.EastGateBiotech.com,86400,65 Harbour Square,,Suite 2203
